76
Views
3
CrossRef citations to date
0
Altmetric
Original Research

Combined administration of PTX and S-HM-3 in TPGS/Solutol micelle system for oncotarget therapy

, &
Pages 1011-1026 | Published online: 07 Feb 2019

References

  • ChemocarePaclitaxel Available from: http://www.chemocare.com/chemotherapy/drug-info/Paclitaxel.aspxAccessed January 1, 2018
  • YeLHeJHuZAntitumor effect and toxicity of Lipusu in rat ovarian cancer xenograftsFood Chem Toxicol20135220020623149094
  • SofiasAMDunneMStormGAllenCThe battle of “nano” paclitaxelAdv Drug Deliv Rev2017122203028257998
  • WangXLiuXLiYSensitivity to antitubulin chemotherapeutics is potentiated by a photoactivable nanoliposomeBiomaterials2017141506228667899
  • BernabeuECagelMLagomarsinoEMorettonMChiappettaDAPaclitaxel: what has been done and the challenges remain aheadInt J Pharm20175261–247449528501439
  • AdrianLHDanieleGInhibitors of tumor angiogenesisNeidleSCancer Drug Design and Discovery2nd edNew YorkAcademic Press2014275317
  • YangWHXuJMuJBXieJRevision of the concept of anti-angiogenesis and its applications in tumor treatmentChronic Dis Transl Med201731334029063054
  • SiimBGLeeAEShalal-ZwainSPruijnFBMckeageMJWilsonWRMarked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA)Cancer Chemother Pharmacol2003511435212497205
  • SandlerAGrayRPerryMCPaclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancerN Engl J Med2006355242542255017167137
  • ReckMvon PawelJZatloukalPOverall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)Ann Oncol20102191804180920150572
  • GaronEBCiuleanuTEArrietaORamucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trialLancet2014384994466567324933332
  • ManegoldCDingemansACGrayJEThe potential of combined immunotherapy and antiangiogenesis for the synergistic treatment of advanced NSCLCJ Thorac Oncol201712219420727729297
  • TrédanOGalmariniCMPatelKTannockIFDrug resistance and the solid tumor microenvironmentJ Natl Cancer Inst200799191441145417895480
  • SharomFJABC multidrug transporters: structure, function and role in chemoresistancePharmacogenomics20089110512718154452
  • YuanHLiXWuJStrategies to overcome or circumvent P-glycoprotein mediated multidrug resistanceCurr Med Chem200815547047618289002
  • AllerSGYuJWardAStructure of P-glycoprotein reveals a molecular basis for poly-specific drug bindingScience200932359221718172219325113
  • WolkingSSchaeffelerELercheHSchwabMNiesATImpact of genetic polymorphisms of ABCB1 (MDR1, P-glycoprotein) on drug disposition and potential clinical implications: update of the literatureClin Pharmacokinet201554770973525860377
  • MuthuMSKulkarniSAXiongJFengSSVitamin E TPGS coated liposomes enhanced cellular uptake and cytotoxicity of docetaxel in brain cancer cellsInt J Pharm2011421233234022001537
  • JinXLiMYinLZhouJZhangZLvHTyroservatide-TPGS-paclitaxel liposomes: Tyroservatide as a targeting ligand for improving breast cancer treatmentNanomedicine20171331105111527845234
  • VardhanHMittalPAdenaSKRUpadhyayMYadavSKMishraBProcess optimization and in vivo performance of docetaxel loaded PHBV-TPGS therapeutic vesicles: a synergistic approachInt J Biol Macromol201810872974329111267
  • LiuHTuLZhouYImproved bioavailability and antitumor effect of docetaxel by TPGS modified Proniosomes: in vitro and in vivo evaluationsSci Rep2017714337228266539
  • Al-AbdAMAlamoudiAJAbdel-NaimABNeamatallahTAAshourOMAnti-angiogenic agents for the treatment of solid tumors: potential pathways, therapy and current strategies – a reviewJ Adv Res20178659160528808589
  • GaccheRNAssarafYGRedundant angiogenic signaling and tumor drug resistance drug resistance updatesDrug Resist Updat201836477629499837
  • HMXuHM-3, angiogenesis inhibitor preparative method and applicationChina Patent2006183048713 Available from: https://worldwide.espacenet.com/publicationDetails/biblio?DB=EPODOC&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20060913&CC=CN&NR=1830487A&KC=AAccessed January 30, 2019
  • XuHMYinRChenLAn RGD-modified endostatin-derived synthetic peptide shows antitumor activity in vivoBioconjug Chem200819101980198618800818
  • ZhuBXuHMZhaoLHuangXZhangFSite-specific modification of anti-angiogenesis peptide HM-3 by polyethylene glycol molecular weight of 20 kDaJ Biochem2010148334134720587645
  • ChandrasekharanPMaityDYongCXChuangKHDingJFengSSVitamin E (d-alpha-tocopheryl-co-poly(ethylene glycol) 1000 succi-nate) micelles-superparamagnetic iron oxide nanoparticles for enhanced thermotherapy and MRIBiomaterials201132245663567221550654
  • MuthuMSKulkarniSALiuYFengSSDevelopment of docetaxel-loaded vitamin E TPGS micelles: formulation optimization, effects on brain cancer cells and biodistribution in ratsNanomedicine20127335336422329606
  • JinXLiMYinLZhouJZhangZLvHTyroservatide-TPGS-paclitaxel liposomes: Tyroservatide as a targeting ligand for improving breast cancer treatmentNanomedicine20171331105111527845234
  • XuHLFanZLZhugeDLTherapeutic supermolecular micelles of vitamin E succinate-grafted ε-polylysine as potential carriers for curcumin: enhancing tumour penetration and improving therapeutic effect on gliomaColloids Surf B Biointerfaces201715829530728711016
  • YangLZhangZHouJTargeted delivery of ginsenoside compound K using TPGS/PEG-PCL mixed micelles for effective treatment of lung cancerInt J Nanomedicine2017127653766729089761
  • HouJSunEZhangZHImproved oral absorption and anti-lung cancer activity of paclitaxel-loaded mixed micellesDrug Deliv201724126126928165804